- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Shanghai Henlius Biotech Inc (2696)
Shanghai Henlius Biotech Inc stock price live, this page displays HK 2696 stock exchange data. View the 2696 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Shanghai Henlius Biotech Inc real time stock price chart below.
What Is the Shanghai Henlius Biotech Inc Stock Price Today?
The Shanghai Henlius Biotech Inc stock price today is 77.90.
What Is the Stock Symbol for Shanghai Henlius Biotech Inc?
The stock symbol for Shanghai Henlius Biotech Inc is ""2696.""
What Stock Exchange Does Shanghai Henlius Biotech Inc Trade On?
Shanghai Henlius Biotech Inc is listed and trades on the Hong Kong stock exchange.
Is Shanghai Henlius Biotech Inc a Good Stock to Buy?
Determining whether Shanghai Henlius Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2696 quote. (ISIN: CNE100003N76)
What Is the Shanghai Henlius Biotech Inc Stock Price Today?
The Shanghai Henlius Biotech Inc stock price today is 77.90.
What Is the Stock Symbol for Shanghai Henlius Biotech Inc?
The stock symbol for Shanghai Henlius Biotech Inc is ""2696.""
What Stock Exchange Does Shanghai Henlius Biotech Inc Trade On?
Shanghai Henlius Biotech Inc is listed and trades on the Hong Kong stock exchange.
Is Shanghai Henlius Biotech Inc a Good Stock to Buy?
Determining whether Shanghai Henlius Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 2696 quote. (ISIN: CNE100003N76)
Hong Kong
Currency in HKD
77.90
+3.90(+5.27%)
Closed·
Fair Value
An estimate of a Henlius Biotech's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
74.00
80.00
52 wk Range
15.20
85.95
2696 Scorecard
Full Analysis
Impressive gross profit margins
2696 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Henlius Biotech's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
74.0080.00
52 wk Range
15.2085.95
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
2696 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Henlius Biotech's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
95.88
Upside
+23.08%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Shanghai Henlius Biotech Inc Company Profile
Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating active glomerulonephritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast, and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn’s disease, and pediatric Crohn’s disease; and HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer. The company also develops HANSIZHUANG, a serplulimab injection to treat colorectal cancer, gastric carcinoma, and limited-stage small cell lung cancer; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat of metastatic gastroesophageal junction cancer and gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX22, HLX42, HLX43, and HLX53 to treat solid tumors; HLX11 to treat breast cancer; HLX14 to treat osteoporosis; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, Europe, and Oceania. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical Development Co., Ltd.
Compare 2696 to Peers and Sector
Metrics to compare | 2696 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2696PeersSector | |
|---|---|---|---|---|
P/E Ratio | 47.0x | −25.5x | −0.5x | |
PEG Ratio | 2.42 | 0.21 | 0.00 | |
Price/Book | 11.4x | 7.4x | 2.6x | |
Price / LTM Sales | 6.7x | 18.6x | 3.3x | |
Upside (Analyst Target) | 23.9% | 3.1% | 38.9% | |
Fair Value Upside | Unlock | −16.4% | 5.4% | Unlock |
Analyst Ratings
6 Buy
0 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 95.88
(+23.08% Upside)
Earnings
Latest Release
Aug 25, 2025
EPS / Forecast
0.72 / --
Revenue / Forecast
2.82B / --
People Also Watch
FAQ
What Stock Exchange Does Henlius Biotech Trade On?
Henlius Biotech is listed and trades on the Hong Kong Stock Exchange stock exchange.
What Is the Stock Symbol for Henlius Biotech?
The stock symbol for Henlius Biotech is "2696."
What Is the Henlius Biotech Market Cap?
As of today, Henlius Biotech market cap is 42.34B.
What Is Henlius Biotech's Earnings Per Share (TTM)?
The Henlius Biotech EPS (TTM) is 1.52.
From a Technical Analysis Perspective, Is 2696 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Henlius Biotech Stock Split?
Henlius Biotech has split 0 times.
How Many Employees Does Henlius Biotech Have?
Henlius Biotech has 3537 employees.
What is the current trading status of Henlius Biotech (2696)?
As of 30 Aug 2025, Henlius Biotech (2696) is trading at a price of 77.90, with a previous close of 74.00. The stock has fluctuated within a day range of 74.00 to 80.00, while its 52-week range spans from 15.20 to 85.95.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.